Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 81 to 90 of 279 total matches.
Intravesical Gemcitabine (Inlexzo) for Bladder Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Oct 27, 2025 (Issue 1740)
Effects: Urinary frequency and urgency, urinary tract
infection and pain, dysuria, and hematuria ...
The FDA has approved Inlexzo, a gemcitabine
intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive
bladder cancer (NMIBC) with carcinoma in situ, with or
without papillary tumors. The Inlexzo system is placed
into the bladder to deliver gemcitabine for 3 weeks.
Med Lett Drugs Ther. 2025 Oct 27;67(1740):e176-7 doi:10.58347/tml.2025.1740c | Show Introduction Hide Introduction
Comparison Table: Some Oral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
: Vasculitis,
chills, alopecia, pruritus,
urticaria, abdominal pain,
bloating, nausea, vomiting,
diarrhea ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Teprotumumab (Tepezza) for Thyroid Eye Disease
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
, that can cause eye
pain, dryness, redness and swelling, diplopia, and in
severe cases, loss of vision ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like
growth factor-1 receptor (IGF-1R) inhibitor, has
been approved by the FDA for IV treatment of thyroid
eye disease. It is the first drug to be approved in the US
for this indication.
Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
trials included applicationsite
pain (10.6%), dryness (4.9%), exfoliation (4.1%),
erythema (4.0 ...
The FDA has approved Twyneo (Galderma), a cream
containing the retinoid tretinoin and the oxidizing
agent benzoyl peroxide, for once-daily topical
treatment of acne in patients ≥9 years old.
A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
, and pain, muscle spasms, insomnia,
abdominal pain, constipation, diarrhea, dizziness,
abnormal dreams ...
A once-weekly transdermal formulation of the
acetylcholinesterase inhibitor donepezil (Adlarity –
Corium) has been approved by the FDA for
treatment of mild, moderate, and severe Alzheimer's
disease (AD) dementia. Donepezil is the second
acetylcholinesterase inhibitor to become available in
a transdermal formulation; transdermal rivastigmine
(Exelon Patch), which is applied once daily, has been
available for years for the same indication. Donepezil
is also available in oral formulations (Aricept, and
generics) for treatment of AD dementia.
Opill — An OTC Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
,
breast tenderness, increased appetite, abdominal pain, and
headache can occur.
Dosage: One 0.075 mg ...
The FDA has approved Opill (Perrigo), a progestin-only
oral contraceptive that contains norgestrel, for
sale over the counter (OTC). Opill is the first oral
contraceptive to be approved in the US for sale without
a prescription. Approval of OTC Opill is intended
to increase access to effective contraception and
reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2 doi:10.58347/tml.2023.1685c | Show Introduction Hide Introduction
Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
: Application-site pain and erythema are
common.
▶ Dosage: Applied to each lesion once daily for up to 12 ...
Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class
nitric oxide-releasing agent, has been approved
by the FDA for topical treatment of molluscum
contagiosum in patients ≥1 year old. It is the second
drug to become available in the US for treatment
of molluscum contagiosum and the first that can
be applied by the patient or caregiver at home;
cantharidin 0.7% solution (Ycanth), which is applied
by a healthcare professional, was approved earlier for
use in patients ≥2 years old.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):113-4 doi:10.58347/tml.2025.1733a | Show Introduction Hide Introduction
Acoramidis (Attruby) for Transthyretin Amyloid Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
: Most common were diarrhea and upper
abdominal pain. Increases in serum creatinine and decreases ...
The FDA has approved acoramidis (Attruby –
BridgeBio), an oral transthyretin stabilizer, to reduce
cardiovascular-related hospitalization and cardiovascular
death in adults with wild-type or variant
(hereditary) transthyretin amyloid cardiomyopathy
(ATTR-CM). Acoramidis is the second transthyretin
stabilizer to be approved in the US for this indication;
tafamidis (Vyndaqel, Vyndamax) was approved
in 2019.
Med Lett Drugs Ther. 2025 Mar 17;67(1724):45-6 doi:10.58347/tml.2025.1724c | Show Introduction Hide Introduction
Avmapki Fakzynja Co-Pack for Ovarian Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
: Nausea, fatigue, rash, diarrhea, musculoskeletal
pain, edema, and serious skin reactions were reported ...
Avmapki Fakzynja Co-Pack (Verastem), a combination
of the kinase inhibitors avutometinib and defactinib,
has received accelerated approval from the FDA for
treatment of KRAS-mutated recurrent low-grade
serous ovarian cancer in women who had previously
received systemic therapy. Neither drug is approved
for use as monotherapy for any indication. Avmapki
Fakzynja is the first treatment to be approved in the
US for this indication.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e120-1 doi:10.58347/tml.2025.1733j | Show Introduction Hide Introduction
Retifanlimab (Zynyz) for Anal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
, musculoskeletal pain, pruritus,
diarrhea, rash, pyrexia, nausea, and urinary tract
infection. Infusion-related ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1)-blocking antibody, has been
approved by the FDA for use in combination with
carboplatin and paclitaxel for first-line treatment of
unresectable locally recurrent or metastatic squamous
cell carcinoma of the anal canal (SCAC) and as
monotherapy in patients who had disease progression
or intolerance to platinum-based chemotherapy. The
drug received accelerated approval for treatment of
recurrent locally advanced or metastatic Merkel cell
carcinoma in 2023.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e126-7 doi:10.58347/tml.2025.1733m | Show Introduction Hide Introduction